..............page:1250-1256
..............page:1245-1249
..............page:1220-1222
..............page:1277-1280
..............page:1237-1242
..............page:1193-1195,1242
..............page:1196-1200
..............page:1257-1261
..............page:1211-1212,1236
..............page:1274-1276
..............page:1180-1181
..............page:1217-1219
..............page:1223-1224
..............page:1201-1203,1210
..............page:1182-1185
..............page:1225-1230
..............page:1186-1188,1273
Management measures of drug risk and its application in the case of Lotronex
wei jing1; 2; pan wei-san3; yang yue1(1 school of business administration; shenyang pharmaceutical university; shenyang 110016; china; 2 liaoning food and drug administration technical evaluation center; shenyang 110003; china; 3 school of pharmacy; shenyang pharmaceutical university; shenyang 110016; china)
..............page:1189-1192
..............page:1204-1210
..............page:1231-1236
Preparation and influence factors of salbutamol sulfate resin
zhang xuan-yi1; zhang xiang-rong1; l juan-li2; lei yang1; li u wei1; pan wei-san1(1 department of pharmaceutics; shenyang pharmaceutical university; shenyang 110016; china; 2 department of pharmacy; general hospital of chinese people s armed police forces; beijing 100039; china)
..............page:1262-1265
..............page:1266-1273
Synthesis of doxercalciferol
sun bo; xu hong gui; wen peng; lu qun(school of life science and engineering; southwest jiaotong university; chengdu 610031; china)
..............page:1243-1244,1276
..............page:1213-1216